Danielle Schramm, MD
Internal Medicine · Troy, MINPI 1134287592
Payments from drug & device makers
Across 137 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$288
- Axsome Therapeutics, Inc.$270
- AbbVie$265
- AstraZeneca$220
- Exact Sciences$173
- GSK$158
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,752100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $288 |
| Axsome Therapeutics, Inc. | 13 | $270 |
| AbbVie | 12 | $265 |
| AstraZeneca | 12 | $220 |
| Exact Sciences | 9 | $173 |
| GSK | 9 | $158 |
| Abbott | 4 | $153 |
| Bayer | 8 | $152 |
| Lilly USA, LLC | 8 | $126 |
| Boehringer Ingelheim | 6 | $120 |
| Pfizer | 7 | $115 |
| Alkermes, Inc. | 4 | $102 |
| Shield Therapeutics Inc | 4 | $87 |
| Verona Pharma, Inc. | 4 | $67 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $60 |
| Sanofi Pasteur Inc. | 3 | $52 |
| Dexcom, Inc. | 1 | $35 |
| Novartis | 2 | $32 |
| Zealand Pharma US, Inc. | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Amgen | 2 | $27 |
| Boston Scientific | 1 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| Cipher Pharmaceuticals US LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Merck | 1 | $15 |
How this compares
$2,752 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 58 | $66,426 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $62,754 |
| JanuviaSitagliptin Phosphate | 37 | $41,082 |
| EliquisApixaban | 39 | $35,019 |
| JardianceEmpagliflozin | 40 | $29,795 |
| XifaxanRifaximin | 12 | $28,105 |
| OzempicSemaglutide | 15 | $23,100 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $23,039 |
| XareltoRivaroxaban | 22 | $18,129 |
| KerendiaFinerenone | 23 | $17,990 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $17,808 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $17,795 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $16,529 |
| LinzessLinaclotide | 21 | $15,779 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 351 | $11,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $158 | $103,601153 claims |
| Lilly USA, LLCTrulicity | $126 | $66,42658 claims |
| MerckJanuvia | $15 | $41,08237 claims |
| Boehringer IngelheimJardiance, Tradjenta | $120 | $38,78752 claims |
| PfizerEliquis | $115 | $35,01939 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $60 | $28,10512 claims |
| Novo NordiskOzempic | $288 | $23,10015 claims |
| BayerKerendia | $152 | $17,99023 claims |
| AstraZenecaBreztri Aerosphere | $220 | $16,52913 claims |
| AbbVieLinzess | $265 | $15,77921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Troy
- Neil FraserTroy$14.3M
- Jay SandbergTroy$8.3M
- John CaladoTroy$198K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.